Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM

ConclusionThe safety profile of DMF in these subgroups was consistent with the overall ESTEEM population. Relapse rates remained low in Black and Hispanic patients, and consistent with non-Black and non-Hispanic patients. These data demonstrate a comparable real-world treatment benefit of DMF in Black and Hispanic patients.Trial RegistrationClinicalTrials.gov identifier NCT02047097.

http://link.springer.com/10.1007/s40120-023-00517-1

Source: Neurology and Therapy - June 24, 2023 Category: Neurology Source Type: research